Application Page

Page last updated: 22 July 2024 (this page is generated automatically and reflects updates to other content within the website)

Application pages in development

MSAC Applications
ID/Title
1782 – Genetic testing to detect estrogen receptor 1 (ESR1) mutations in patients with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, to determine eligibility for treatment with PBS subsidised elacestrant
1783 – Genetic testing to detect PIK3CA mutations in patients with hormone receptor (HR)-positive, HER-2 negative, locally advanced or metastatic breast cancer, to determine eligibility for treatment with PBS subsidised inavolisib
1781 – Risk assessment in prostate cancer using the Stockholm3 multiparametric blood test
1779 – Testing of tumour tissue to detect FGFR2 fusions or rearrangements in people with cholangiocarcinoma, to determine eligibility for treatment with PBS subsidised futibatinib
1778 – Fibroblast growth factor 23 (FGF-23) testing for patients with a high pre-test probability of X-linked hypophosphatemia (XLH) to determine eligibility for burosumab on the Pharmaceutical Benefits Scheme (PBS)
1777 – Review of MBS items for clinically indicated gross and histologic examination of placentas in perinatal deaths
1738 – Two testing options to detect early-stage Alzheimer's Disease, to determine eligibility for PBS subsidised lecanemab treatment
1732.1 – Imlifidase as a desensitisation treatment to enable kidney transplant in highly sensitised adult transplant candidates
1775 – Newborn bloodspot screening for mucopolysaccharidosis, Type 1 (MPS I)
1776 – Newborn bloodspot screening for mucopolysaccharidosis Type II (MPS II)
1774 – Newborn bloodspot screening for glycogen storage disease, Type II (Pompe disease)
1773 – Autologous chondrocyte implantation for symptomatic articular cartilage defects greater than 2cm2 of the knee
1751 – Valoctocogene roxaparvovec gene therapy for congenital haemophilia A
1771 – Axicabtagene ciloleucel therapy for patients with relapsed or refractory follicular lymphoma
1772 – Single chamber leadless pacing with atrio-ventricular synchronous pacing in patients with bradycardia
1770 – Valve-in-valve transcatheter aortic valve implantation using a balloon-expanding transcatheter heart valve system for patients with severe, symptomatic aortic stenosis
1769 – Human leukocyte antigen testing for sensitivity to carbamazepine in patients with epilepsy
1507.1 – Germline BRCA mutation testing in patients with locally advanced or metastatic HER2-negative breast cancer to determine eligibility for PBS-listed olaparib treatment
1767 – Immunohistochemistry testing for Claudin 18 expression in patients with gastric or gastro-oesophageal junction cancers, to determine eligibility for PBS subsidised zolbetuximab treatment
1766 – Genetic testing to detect AKT-pathway alterations in patients with hormone receptor-positive, HER2-negative advanced breast cancer, to determine eligibility for PBS subsidised capivasertib treatment
1765 – Amendment of MBS items 73303 and 73304 (BRCA1/2 mutation testing in patients with metastatic castration-resistant prostate cancer) to include talazoparib
1627.1 – Point-of-care testing for sexually transmitted infections provided by Aboriginal Medical Services or Aboriginal Community Controlled Heath Services in rural or remote areas
1737.1 – Newborn bloodspot screening for Sickle Cell Disease
1722.1 – Axicabtagene ciloleucel (Yescarta®) for relapsed or refractory large B-cell lymphoma
1720 - 68Ga PSMA-11 PET/CT imaging for patients who are candidates for PSMA targeted therapy
1764 - Micro-bypass glaucoma surgery device implantation into the suprachoroidal space as a standalone procedure in patients with open angle glaucoma
1662.2 – The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques
1523.1- Transluminal insertion, management and removal of an intravascular microaxial blood pump (Impella®), for patients requiring mechanical circulatory support
1763 – Amendment of MBS Item 11512 to include the use of portable home spirometry via telehealth
1754 - Patient consultations and surgical procedures for gender affirmation in adults with gender incongruence
1761 - Faecal calprotectin for the monitoring of disease activity in patients with inflammatory bowel disease
1760 - DPYD genotyping to predict fluoropyrimidine-induced toxicity
1743 - Optical coherence tomography (OCT) guided coronary stent insertion for patients eligible for coronary revascularisation
1734 – Intravascular lithotripsy for the treatment of moderately or severely calcified peripheral artery disease
1758 - Expansion of MBS item numbers 12320 & 12322 for bone mineral density testing to include patients aged 60-69 years
1690.1 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma
1723.1 - Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia
1750 - Testing of tumour tissue to detect IDH1 mutations in patients with cholangiocarcinoma to determine eligibility for ivosidenib on the Pharmacutical Benefits Scheme
1593.1 – Bioinductive implant for the repair of rotator cuff tear
1749 – Insertion of durable left ventricular assist device for use as destination therapy
1748 – Review of Tisagenlecleucel for treatment of confirmed relapsed/refractory CD19-positive acute lymphoblastic leukaemia in children and young adults up to 25 years old
1747 – Permanent Medicare Benefits Schedule (MBS) items for COVID-19 nucleic acid testing
1686.1 –177 Lutetium PSMA i&t for metastatic castrate resistant prostate cancer
1689.1 – Quantification of NT-proBNP in patients with diagnosed pulmonary arterial hypertension for ongoing risk assessment
1752 – Anal human papillomavirus (HPV) and cytology testing in high-risk populations to determine access to high-resolution anoscopy and ablative treatment to prevent anal cancer
1741 – Continuous nerve blockade using a catheter technique
1740 – N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP) to aid in the diagnosis of patients with suspected heart failure in a non-hospital setting
1739 – Percutaneous electrical nerve stimulation therapy for chronic neuropathic pain
1728 – Etranacogene dezaparvovec for the treatment of Haemophilia B
1744 – 177Lutetium(nca)-DOTA-octreotate treatment for advanced neuroendocrine tumours and other high somatostatin receptor expressing tumours
1549 – PD-L1 immunohistochemistry testing for access to pembrolizumab in combination with chemotherapy for first line treatment of triple negative breast cancer
1658.1 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib
1726 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, for access to PBS niraparib
1724 – Cardiac technical support services provided by industry employed technicians
1737 – Newborn bloodspot screening for Sickle Cell Disease and Beta Thalassaemia
1736 – Lipoprotein(a) testing as an independent predictor of cardiovascular disease
1727 – Deep brain stimulation for treatment-refractory obsessive compulsive disorder
1732 – Imlifidase as a desensitisation treatment to enable kidney transplant in highly sensitised adult transplant candidates
1725 – Transanal total mesorectal excision for the treatment of rectal cancer and benign disease
1718 – PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for persistent, recurrent, or metastatic cervical cancer, to determine eligibility for pembrolizumab treatment
1677.1 – Pharmacy Diabetes Screening Trial
1723 – Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia
1525.1 – Low dose rate brachytherapy for intermediate and high-risk prostate cancer
1662.1 – The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques
1722 – Axicabtagene ciloleucel (Yescarta®) for relapsed or refractory large B-cell lymphoma
1719 – Insertion of a bioabsorbable implant for nasal airway obstruction due to lateral wall insufficiency
1710 – Newborn bloodspot screening for X-linked adrenoleukodystrophy
1716 – Germline BRCA mutation test to detect BRCA1 or BRCA2 mutations in patients with HER2- negative high risk early breast cancer to determine eligibility for PBS-listed olaparib treatment
1714 – National Blood Authority listing for Obizur® (susoctocog alfa) for treatment of bleeding episodes with acquired Haemophilia A
1717 – Extravascular implantable cardioverter defibrillator therapy for patients at risk of ventricular arrhythmia
1721 – Small gene panel testing for non-small cell lung carcinoma
1713 – Cardiac MRI in the diagnosis of myocarditis
1712 – Out-of-laboratory sleep studies in the diagnosis and management of sleep disordered breathing in children & adolescents
1408.1 – A prognostic RT-qPCR test for prediction of risk of distant recurrence of breast cancer under endocrine treatment
1709 – Somatic gene testing for the diagnosis of glioma, including glioblastoma
1711 – Review of MBS items for subacromial decompression
1706 – Angiogenic and anti-angiogenic markers for identification and management of preeclampsia
1705 – Structured prenatal risk assessment for preterm preeclampsia
1701 – Deep brain stimulation of the thalamus for the treatment of severe refractory epilepsy
1700 – Totally thoracoscopic exclusion of the left atrial appendage for patients with non-valvular atrial fibrillation
1708 – Hepatitis Delta Virus (HDV) RNA PCR testing to determine eligibility for PBS-subsidised bulevirtide (HEPCLUDEX) for treatment of HDV
1702 – Abdominal MRI for rare genetic conditions associated with increased risk of renal tumours
1703 – Detection of measurable residual disease in patients with acute lymphoblastic leukaemia
1707 – Detection of measurable residual disease in patients with acute lymphoblastic leukaemia
1695 – Procedures for the implantation and refill-exchange of the Port Delivery System with ranibizumab to treat neovascular age-related macular degeneration
1678 – Integrating Pharmacists within Aboriginal Community Controlled Health Services to Improve Chronic Disease Management (IPAC Project)
1698 – Chronic Pain MedsCheck Trial
1699 – National Lung Cancer Screening Program
1679 – Improved medication management for Aboriginal and Torres Strait Islanders Feasibility Study (IMeRSe Feasibility Study)
1614.1 – Magnetic resonance-guided focused ultrasound for the treatment of medically refractory essential tremor
1686 –177 Lutetium PSMA i&t for metastatic castrate resistant prostate cancer
1690 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma
1684 – Genetic testing for variants associated with haematological malignancies
1675 – Whole Genome Sequencing for the diagnosis of mitochondrial disease
1683 – MRI of the liver, for the evaluation of hepatic metastases for initial staging or restaging prior to treatment using interventional techniques
1682 – Amendment to MBS Item 63464 – MRI for the detection of breast cancer in asymptomatic high-risk patients
1685 – Ventral rectopexy for the treatment of rectal prolapse and intussusception
1691 – PromarkerD testing in patients with type 2 diabetes to determine the risk of developing diabetic kidney disease
1689 – Quantification of NT-proBNP in patients with systemic sclerosis, and in patients with diagnosed pulmonary arterial hypertension
1697 – Review of different minimally invasive therapeutic approaches for the management of patients with benign prostatic hyperplasia
1680 – Genetic testing for childhood hearing impairment
1665 – Radiofrequency echographic multi spectrometry for bone density measurement and determination of osteopenia/osteoporosis
1555.1 – Endoscopic sleeve gastroplasty for the treatment of patients with Class I and II obesity who have failed first line (lifestyle modification) and second line (pharmacotherapy) treatments
1677 – Pharmacy Diabetes Screening Trial
1602.1 – Testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusion status, in patients with locally advanced or metastatic solid tumours, to determine eligibility for larotrecti